Medtronic is a device company, not a pharmaceutical company. Perhaps thats whu they decided to fund only a subpart of the trial. Yes. it's chump change for them, but they would have to relicense it. I'll guess that someone at MDT had a relationship with the CEO of ABIO and wanted to help them out, but I wouldn't expect them to fund the whole trial, even if it's chump change for them. Of course, having a marquis name helps, but I'd guess it would be a big pharma partner who would step up for the 9 figures required for a phase 3 trial and approval. The indication of a fib is huge, no doubt and trial design will play a key role. I'm buying today too. They're no longer in limbo.